news
Scientists in the U.S. have developed molecules, termed cyclic peptoids,…
25 October 2018 | By Drug Target Review
Scientists in the U.S. have developed molecules, termed cyclic peptoids, that block the action of genes that drive the growth of therapy-resistant prostate cancer, according to a new study.